Allogene Therapeutics Reports Positive Results from Phase 1

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

New York , United States , American , Christine Cassiano , Allogene Allo , Rafael Amado , Allogene Therapeutics Inc , Linkedin , Drug Administration , Research Development , Nasdaq , American Society Of Hematology , Physician At Memorial Sloan Kettering Cancer Center , Company To Hosta Conference Call , First Allogeneic , Demonstrate Safety , Substantial Efficacy , Multiple Myeloma , Data Demonstrate Responses Similar , Approved Autologous , Well Tolerated , Overall Response Rate , Very Good Partial Response , Complete Response , Stringent Complete Response , Were Minimal Residual Disease , Five Days , Conference Call , Webcast Today , Allogene Therapeutics , Sham Mailankody , Assistant Attending Physician , Memorial Sloan Kettering Cancer Center , American Society , Annual Meeting , Executive Vice President , Chief Medical Officer , Minimal Residual Disease , Regenerative Medicine Advanced Therapy , Springworks Therapeutic , Monday December , Orphan Drug Designation , South San Francisco , Forward Looking Statements , Private Securities Litigation Reform Act , Investor Contact ,